Status:
UNKNOWN
Fecal DNA Methylation Test for Colorectal Cancer Screening
Lead Sponsor:
Tri-Service General Hospital
Conditions:
Colorectal Cancer
Colorectal Adenoma
Eligibility:
All Genders
40-79 years
Brief Summary
This is an observational, prospective study using fecal DNA methylation test to define the risk of suffering from advanced adenoma or colorectal cancer (CRC) compared to colonoscopy and fecal immunoch...
Detailed Description
The incidence rate and the mortality rate of colorectal cancer (CRC) have been steadily increasing worldwide. Early detection of CRC can provide great opportunities to help patients, increasing their ...
Eligibility Criteria
Inclusion
- Participants with age over 40 but under 80, who need to take colonoscopy or diagnostic confirmed colorectal cancer patient.
Exclusion
- Participants who are undergoing cancer treatments or have diagnosed with cancer, received cancer treatment in the past.
- Participants who have received any cancer treatments, including chemotherapy and radiotherapy before taking surgery.
- Participants have received any surgery for colorectal cancer in the past.
- Pregnant women or nursing women.
Key Trial Info
Start Date :
March 31 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 20 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04823793
Start Date
March 31 2021
End Date
March 20 2023
Last Update
April 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tri-Service General Hospital, National Defense Medical Center
Taipei, Taiwan